News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …
MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …
MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …
MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …
* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …
MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …
Wasatch Advisors LP significantly increased its stake in MacroGenics (NASDAQ:MGNX) during the second quarter, purchasing an additional 459,180 shares to bring its total ownership to over 2 million shares, valued at approximately $9.3 million. This increase means Wasatch Advisors now owns 3.18% of the …
MacroGenics, Inc. announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics. This program incorporates MacroGenics’ TRIDENT® platform and targets solid tumors. MacroGenics remains eligible for up to …
MacroGenics Inc. shares rose 4.3% after Gilead Sciences exercised its option on a preclinical bispecific program, resulting in a $10 million payment to MacroGenics. This exercise is part of a 2022 collaboration agreement, under which MacroGenics could receive up to $1.6 billion in additional …
MacroGenics Inc is projected to report a loss of 13 cents per share. This information is part of an earnings preview, indicating an upcoming financial announcement from the company. The full article is available through a subscription to TradingView.
MacroGenics (NASDAQ:MGNX) is anticipated to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts project a loss of approximately $0.08 per share and revenue of about $59.1 million. The company's prior quarter missed EPS expectations but exceeded revenue estimates, and …
A holder of MacroGenics Inc. (NASDAQ: MGNX) has filed a notice under Rule 144 to sell up to 20,166 shares of common stock through Merrill Lynch. The proposed sale date is August 3, 2026, on NASDAQ. These shares were acquired through stock plan activity …
Bank of America Corporation has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock, which constitutes 4.0% of the class. This stake is held through various wholly-owned subsidiaries and Bank of America reports shared voting and …
MacroGenics, Inc. (NASDAQ:MGNX) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $5.50. This comes after some analysts raised their price targets and upgraded ratings, while others maintained a sell rating. The biopharmaceutical company recently reported a …
TradingKey reports that MacroGenics Inc (MGNX) has a current financial score of 7.98, placing it 66th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 57.48% year-over-year …
BlackRock, Inc. has disclosed a 7.1% beneficial ownership stake in MacroGenics Inc. (MGNX), holding 4,503,913 shares of common stock as of June 30, 2026. This information was reported in a Schedule 13G filing, indicating that BlackRock has sole voting power over 4,447,312 shares and …
This article provides a comprehensive stock analysis of MacroGenics Inc (MGNX) from TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status. Despite recent market weakness, the company's revenue and net income have seen significant growth, and analysts have issued "Buy" ratings …
This article analyzes market sentiment for MacroGenics (MGNX) through analyst consensus, short interest, options flow, and recent insider activity. It highlights a "Buy" consensus from 14 analysts with an average price target of $8, significant short interest of 9.3%, and bullish options flow. The …
MacroGenics, Inc. (NASDAQ: MGNX) generated $149.50 million USD in revenue last year. The majority of this revenue, $87.18 million USD, came from its Collaborative and Other Agreements segment. The United States was the largest geographical contributor, accounting for the entire $149.50 million USD of …
Citizens has reiterated a Market Perform rating on MacroGenics Inc. (NASDAQ:MGNX) ahead of the ESMO 2026 conference, where MacroGenics will present data for its MGC026 antibody-drug conjugate and lorigerlimab LINNET study. The firm notes that MacroGenics shares are currently trading at a significant discount …
This article provides a detailed quarterly and annual cash flow statement for MacroGenics Inc (MGNX), allowing users to evaluate the company's financial health and stability. It includes data on operating, investing, and financing cash flows, along with a definition and explanation of each cash …
This page provides an income statement for MacroGenics Inc (MGNX), detailing its quarterly and annual financial performance. It includes metrics like total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The data allows investors to analyze the company's operational …
MacroGenics Inc (MGNX) currently holds an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.70%, marking a 14.58% increase quarter-over-quarter. James Simons is the largest institutional shareholder.
MacroGenics (MGNX) shares fell by nearly 6% following the release of updated results from an ongoing Phase 1 trial for its lead asset, MGC026. The drug, an antibody-based therapy, is being developed to target solid tumors. The trial data involved 74 patients.
MacroGenics, Inc. announced a clinical update on its ongoing Phase 1 study for MGC026, a B7-H3-directed antibody-drug conjugate (ADC), for advanced solid tumors. Interim results, showing the achievement of a pre-specified response threshold in squamous cell carcinoma of the head and neck, will be …
MacroGenics (MGNX) is a small-cap biotech company whose stock performance is heavily influenced by pipeline execution, balance sheet health, and financial metrics like revenue and cash use. Investors should focus on the company's reported numbers, program milestones, and clinical data readouts rather than broad …
MacroGenics Inc. announced that its Phase 1 study for MGC026, an antibody-drug conjugate, met the pre-specified response threshold in the head and neck cancer cohort, allowing it to advance to Stage 2 enrollment. Interim results from the study, which has enrolled 74 patients, will …
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G for MacroGenics (MGNX), disclosing a collective beneficial ownership of 2,374,296 shares, which represents 3.7% of the outstanding common stock. This filing indicates that the reporting persons now …
MacroGenics stock experienced gains following an FDA priority review for vobramitamab duocarmazine and significant revenue increases. The company reported a 31.1% rise in Q1 2024 revenue, totaling $45.7 million, with collaborative and licensing arrangements being the primary driver. This financial performance, coupled with reduced …
Search by ticker symbol or company name and select a result to open its chart.